Literature DB >> 23690185

Evaluation of gastric and small bowel transit times in coeliac disease with the small bowel PillCam®: a single centre study in a non gluten-free diet adult Italian population with coeliac disease.

R Urgesi1, R Cianci, A Bizzotto, G Costamagna, M E Riccioni.   

Abstract

BACKGROUND: The mechanisms underlying bowel disturbances in coeliac disease are still relatively unclear. Past reports suggested that small bowel motor abnormalities may be involved in this pathological condition; there are no studies addressing small bowel transit in coeliac disease before and after a gluten-free diet. AIM: The objective of this study was to determine whether capsule endoscopy (CE) could serve as a test for measurement of gastric and small bowel transit times in a group of symptomatic or asymptomatic coeliac patients at the time of diagnosis with respect to a control group. PATIENTS AND METHODS: Thirty coeliac untreated patients and 30 age-, sex- and BMI-matched healthy controls underwent CE assessment of whole gut transit times.
RESULTS: All subjects completed the study per protocol and experienced natural passage of the pill. No statistical significant differences between gastric emptying and small bowel transit times both in coeliac and control group were found (p = 0.1842 and p = 0.7134; C.I. 95%, respectively). No correlation was found in coeliac patients and control group between transit times and age, sex and BMI. By using the Pearson's correlation test, significant correlation emerged between gastric emptying time and small bowel transit times in coeliac disease (r = 0.1706).
CONCLUSIONS: CE reveals unrecognized gender differences and may be a novel outpatient technique for gut transit times' assessment without exposure to radiation and for the evaluation of upper gut dysfunction in healthy patients suffering from constipation without evidence of intestinal malabsorption. Nevertheless, CE does not seem to be the most suitable method for studying gut transit times in untreated coeliac patients; this might be ascribed to the fact that CE consists of inert (non-digestible, non-absorbable) substances.

Entities:  

Mesh:

Year:  2013        PMID: 23690185

Source DB:  PubMed          Journal:  Eur Rev Med Pharmacol Sci        ISSN: 1128-3602            Impact factor:   3.507


  4 in total

Review 1.  Dyspepsia and celiac disease: Prevalence, diagnostic tools and therapy.

Authors:  Laura Petrarca; Raffaella Nenna; Gerarda Mastrogiorgio; Matteo Florio; Manuela Brighi; Stefano Pontone
Journal:  World J Methodol       Date:  2014-09-26

2.  Fecal Gluten Peptides Reveal Limitations of Serological Tests and Food Questionnaires for Monitoring Gluten-Free Diet in Celiac Disease Patients.

Authors:  Isabel Comino; Fernando Fernández-Bañares; María Esteve; Luís Ortigosa; Gemma Castillejo; Blanca Fambuena; Carmen Ribes-Koninckx; Carlos Sierra; Alfonso Rodríguez-Herrera; José Carlos Salazar; Ángel Caunedo; J M Marugán-Miguelsanz; José Antonio Garrote; Santiago Vivas; Oreste Lo Iacono; Alejandro Nuñez; Luis Vaquero; Ana María Vegas; Laura Crespo; Luis Fernández-Salazar; Eduardo Arranz; Victoria Alejandra Jiménez-García; Marco Antonio Montes-Cano; Beatriz Espín; Ana Galera; Justo Valverde; Francisco José Girón; Miguel Bolonio; Antonio Millán; Francesc Martínez Cerezo; César Guajardo; José Ramón Alberto; Mercé Rosinach; Verónica Segura; Francisco León; Jorge Marinich; Alba Muñoz-Suano; Manuel Romero-Gómez; Ángel Cebolla; Carolina Sousa
Journal:  Am J Gastroenterol       Date:  2016-09-20       Impact factor: 10.864

3.  Variation in small bowel transit time on capsule endoscopy.

Authors:  Kentaro Tominaga; Hiroki Sato; Hiroshi Yokomichi; Atsunori Tsuchiya; Tomoaki Yoshida; Yuzo Kawata; Takeshi Mizusawa; Junji Yokoyama; Shuji Terai
Journal:  Ann Transl Med       Date:  2020-03

Review 4.  The opioid effects of gluten exorphins: asymptomatic celiac disease.

Authors:  Leo Pruimboom; Karin de Punder
Journal:  J Health Popul Nutr       Date:  2015-11-24       Impact factor: 2.000

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.